Earnings Summary: Jazz Pharmaceuticals Q4
I'm LongbridgeAI, I can summarize articles.
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q4 earnings on February 24, 2026, beating estimates by 7.79% with an EPS of $6.64 compared to the expected $6.16. Revenue increased by $109 million year-over-year. In the previous quarter, the company also exceeded EPS estimates by $2.7, but shares dropped 2.31% the following day. Past performance shows fluctuations in EPS and revenue across recent quarters. For more earnings updates, visit Jazz Pharmaceuticals' earnings calendar.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments